NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Date/Time:

 Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT

 

Pre-Registration:

Participants can pre-register for the conference call here:

 

Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

 

Dial In:

Those who choose not to pre-register can access the live conference call by dialing the following and requesting conference call ID# 85516:

888-500-3691 from within the U.S.

646-307-1951 from outside the U.S. 

The live webcast of the conference call also will be available on the Events section of the Company website. A replay of the call will be available beginning three hours after its completion through June 9, 2024 by dialing 877-660-6853 from within the U.S. or 201-612-7415 from outside the U.S., and entering conference ID 13746453. The webcast will also be archived here.

About NovaBay Pharmaceuticals, Inc:

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon.com. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. More information about NovaBay is available here.

Socialize and Stay Informed on NovaBays Progress

Like us on Facebook

Follow us on X

Connect with NovaBay on LinkedIn

Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email sales@avenova.com

Avenova.com

Contacts

NovaBay

Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

jhall@novabay.com

Investor

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.